Home › Compare › SRGRF vs ABBV
SRGRF yields 0.43% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SRGRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SRGRF + ABBV for your $10,000?
Sunpower Group Ltd. provides environmental protection solutions in the People's Republic of China, the United States, Canada, India, Southeast Asia, the Middle East, Europe, South America, and Oceania. It operates through Manufacturing & Services and Green Investments segments. The company's Manufacturing & Services segment develops heat exchangers, pressure vessels, heat pipes, heat pipe exchangers, pipeline energy saving, and related environmental protection products. This segment also offers solutions for flare and flare gas recovery system, zero liquid discharge system, petrochemical engineering, energy saving system, desulphurization, and denitrification systems. Its Green Investments segment focuses on the investment, development, and operation of centralized heat, steam, and electricity generation plants. In addition, it offers design, consultancy, and technology services to the thermal power, construction materials, architecture, municipal engineering, and other industries. Further, the company provides design, consultation, and technology services; produces and sells foam glass products; and supplies heat and electricity to enterprises. It serves chemicals, textiles, textile printing and dyeing, food, paper-making, paints, pharmaceuticals, leather, wood processing, plastic recycling, fodder, chemical fertilizers, and rubber industries. Sunpower Group Ltd. was founded in 1997 and is headquartered in Nanjing, the People's Republic of China.
Full SRGRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.